Marco Katada
Psychiatric/Mental Health · Garden City, KSNPI 1003224932
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 643 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,693, 2.9 times the $1,274 reported in 2021. Among psychiatric/mental health clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 643 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$965
- Alkermes, Inc.$831
- plus $5K from 25 others
What the payments were for
- Food & beverage$11,58899%
- Education$1021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 71 | $1,596 |
| AbbVie | 91 | $1,322 |
| Teva Pharmaceuticals USA, Inc. | 41 | $1,150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $1,008 |
| Otsuka America Pharmaceutical, Inc. | 60 | $965 |
| Alkermes, Inc. | 40 | $831 |
| Lundbeck LLC | 38 | $758 |
| Johnson & Johnson(2 entities) | 38 | $575 |
| Corium, LLC | 20 | $440 |
| E.r. Squibb & Sons, L.L.C. | 24 | $390 |
| Axsome Therapeutics, Inc. | 20 | $306 |
| Bausch Health US, LLC | 20 | $269 |
| Vanda Pharmaceuticals Inc. | 14 | $232 |
| Merck | 12 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $198 |
| Noven Therapeutics, LLC | 11 | $198 |
| Sunovion Pharmaceuticals Inc. | 8 | $153 |
| Almatica Pharma LLC | 6 | $120 |
| Alfasigma USA, Inc. | 7 | $118 |
| Idorsia Pharmaceuticals US Inc | 7 | $118 |
| Neos Therapeutics, LP | 6 | $117 |
| Ironshore Pharmaceuticals Inc. | 7 | $116 |
| Avanir Pharmaceuticals, Inc. | 7 | $107 |
| Supernus Pharmaceuticals, Inc. | 6 | $86 |
| Indivior Inc. | 3 | $81 |
| Tris Pharma Inc | 4 | $65 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| Eisai Inc. | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Orexo US, Inc. | 1 | $20 |
| Pear Therapeutics (US), Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$422
- Austedo XR$123
How this compares
$11,691 in reported general payments places this provider in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 32 | $252,497 |
| AustedoDeutetrabenazine | 18 | $203,401 |
| IngrezzaValbenazine Tosylate | 13 | $112,037 |
| RexultiBrexpiprazole | 16 | $49,068 |
| Abilify MaintenaAripiprazole | 12 | $33,528 |
| AuvelityDextromethorphan Hbr/Bupropion | 30 | $30,833 |
| VraylarCariprazine Hcl | 12 | $20,205 |
| Lurasidone Hcl | 29 | $14,458 |
| BelsomraSuvorexant | 14 | $5,720 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 31 | $4,491 |
| Clozapine | 29 | $2,483 |
| Bupropion XlBupropion Hcl | 79 | $1,934 |
| Buspirone Hcl | 82 | $1,731 |
| Duloxetine Hcl | 70 | $1,522 |
| Quetiapine Fumarate | 79 | $1,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,150 | $455,89850 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,596 | $112,03713 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $965 | $82,59628 claims |
| Axsome Therapeutics, Inc.Auvelity | $306 | $30,83330 claims |
| AbbVieVraylar | $1,322 | $20,20512 claims |
| MerckBelsomra | $213 | $5,72014 claims |
| Almatica Pharma LLCSertraline Hcl | $120 | $89172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Garden City
- Eric ThomasonPittsburg$333K
- Belinda BagbyHutchinson$39K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Louise MuhoziKansas City$14K
- Theresa MuellerOverland Park$14K
- Shiney ZchariaOlathe$14K
- Deborah MurphyWichita$13K
- Marijen AgaShawnee$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.